A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

121

Participants

Timeline

Start Date

October 26, 2022

Primary Completion Date

March 7, 2027

Study Completion Date

March 7, 2029

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

SC Mosunetuzumab

Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)

DRUG

IV Glofitamab

Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)

DRUG

Iberdomide

Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)

DRUG

Golcadomide

Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)

DRUG

Obinutuzumab

Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)

DRUG

Tocilizumab

Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)

Trial Locations (26)

20132

RECRUITING

Irccs Ospedale San Raffaele, Milan

25123

RECRUITING

ASST Spedali Civili di Brescia, Brescia

28027

RECRUITING

Clinica Universidad de Navarra-Madrid, Madrid

28040

RECRUITING

Hospital General Universitario Gregorio Maranon, Madrid

28204

RECRUITING

Levine Cancer Institute, Charlotte

33612

RECRUITING

Moffitt Cancer Center, Tampa

37007

RECRUITING

Hosp Universitario Salamanca, Salamanca

40138

RECRUITING

IRCCS Azienda Ospedaliero Universitaria di Bologna, Bologna

46026

RECRUITING

Hospital Universitario La Fe, Valencia

47014

RECRUITING

"IRCCS Istituto Romagnolo per lo studio dei tumori Dino Amadori", Meldola

56126

RECRUITING

Azienda Ospedaliero Universitaria Pisana-Ospedale Santa Chia, Pisa

60637

RECRUITING

The University of Chicago, Chicago

77030

RECRUITING

UT MD Anderson Cancer Center, Houston

80045

RECRUITING

University of Colorado, Aurora

94143

RECRUITING

UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program, San Francisco

3109600

RECRUITING

Rambam Health Care Campus, Haifa

5262199

RECRUITING

Center Hospital, Ramat Gan

6423900

RECRUITING

Sourasky Medical Center, Tel Aviv

9112001

RECRUITING

Hadassah Medical Center, Jerusalem

0084101

RECRUITING

Soroka, Beersheba

08908

RECRUITING

ICO L'Hospitalet, L'Hospitalet de Llobregat

08035

RECRUITING

Hospital Universitari Vall d Hebron, Barcelona

G12 0YN

RECRUITING

NHS Greater Glasgow and Clyde, Glasgow

W1T 7HA

RECRUITING

University College London Hospitals, London

NG5 1PB

RECRUITING

Nottingham University Hospitals City Campus, Nottingham

OX3 7LE

RECRUITING

Oxford University Hospitals NHS Trust;Churchill Hospital, Oxford

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY